CNTN NASDAQ
Canton Strategic Holdings Inc
1W: +10.4%
1M: -29.0%
3M: -1.0%
YTD: -43.5%
1Y: -38.2%
3Y: -97.2%
$1.91
+0.09 (+4.95%)
Pre-Market: $1.97 (+0.06, +3.40%)
Weekly Expected Move ±12.7%
$1
$2
$2
$2
$2
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: insufficient price history. Altman Z'' 2.95.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
11 relationships11
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2023-05-01
Earliest Filing
2026-03-03
Latest Filing
partner: 10
supplier: 1
Counterparties (Filed by CNTN)
11 relationshipsCompanies named in CNTN's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Clear Street LLC | — | partner | Sales Agent in the Amended and Restated Sales Agreement | 2026-03-03 | View |
| Virtu Americas LLC | — | partner | Sales Agent in the Amended and Restated Sales Agreement | 2026-03-03 | View |
| Clear Street LLC | — | partner | Sales Agent for the issuance and sale of shares | 2025-11-07 | View |
| President Street Global, LLC | — | partner | Sales Agent for the issuance and sale of shares | 2025-11-07 | View |
| Intract Pharma | — | partner | Tharimmune acquired a global license to Intract's delivery platform and supply agreement for infliximab to develop an or | 2024-09-16 | View |
| Janssen Biotech | — | supplier | Sells Infliximab (Remicade) which is the subject of the licensing agreement. | 2024-09-16 | View |
| OmniAb, Inc. | OABIW | partner | Tharimmune has a license agreement with OmniAb to access antibody discovery technology. | 2024-09-16 | View |
| Applied Biomedical Science Institute | — | partner | 501(c)(3) non-profit organization entering R&D collaboration and license agreement | 2023-07-11 | View |
| Hillstream BioPharma Inc. | — | partner | Delaware corporation entering R&D collaboration and license agreement | 2023-07-11 | View |
| Hillstream BioPharma, Inc. | HILS | partner | Company issuing common stock and warrants in an underwriting agreement | 2023-05-01 | View |
| ThinkEquity LLC | — | partner | Representative of the several underwriters purchasing firm securities | 2023-05-01 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-14 | Earnings Release; Exhibits | View | |
| 2026-07-23 | Material Agreement; Acquisition/Disposition; Other Events; Exhibits | Agreement Acquisition | View |
| 2026-07-17 | Shareholder Vote; Other Events | View | |
| 2026-06-16 | Regulation FD; Other Events; Exhibits | View | |
| 2026-03-31 | Other Events; Exhibits | View | |
| 2026-03-03 | Other Events; Financial Statements and Exhibits | View | |
| 2026-03-03 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2026-02-18 | Amendments to Articles of Incorporation or Bylaws; Regulation FD Disclosure; Financial Statements an | View | |
| 2026-02-06 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Other Events; Fi | View | |
| 2026-02-02 | Submission of Matters to a Vote of Security Holders; Other Events; Financial Statements and Exhibits | View | |
| 2026-01-26 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-22 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2026-01-20 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-15 | Notice of Delisting or Transfer | View | |
| 2025-12-12 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-11-10 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-11-07 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-11-06 | Entry into Material Definitive Agreement; Departure/Election of Directors; Appointment of Officers; | Agreement | View |
| 2025-11-05 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-03 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Fin | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR